Michael Egholm sold $5,150 of LAB
President & CEO at STANDARD BIOTOOLS INC.. 5,473 shares at an average of $0.94, traded May 23, 2025, filed May 28, 2025.
Score components
- +25RoleCEO
- 0Trade size$5k at market
- 0Share of holdings soldSold 0.2% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-078457, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 23, 2025 | SOpen-market sale Common Stock | -5,473 | $0.94 | $5,150 | 2,741,191 | May 28, 2025 |
Related signals
Other insiders at STANDARD BIOTOOLS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | STANDARD BIOTOOLS INC. | Hanjoon Alex Kim Chief Financial Officer | $1,344 1,428 shares | -0% | |
| 33Weak | STANDARD BIOTOOLS INC. | Michael Egholm President & CEO | $5,126 5,116 shares | -0% | |
| 30Weak | STANDARD BIOTOOLS INC. | Hanjoon Alex Kim Chief Financial Officer | $1,358 1,355 shares | -0% | |
| 33Weak | STANDARD BIOTOOLS INC. | Michael Egholm President & CEO | $4,861 4,719 shares | -0% | |
| 30Weak | STANDARD BIOTOOLS INC. | Hanjoon Alex Kim Chief Financial Officer | $1,449 1,407 shares | -0% | |
| 43Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $5.1M 4,820,959 shares | +9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.